Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998–2001 U.S. Surveillance Study

Jacobs, Michael; Bajaksouzian, Saralee; Windau, Anne; Good, Caryn E.; Lin, Gengrong; Pankuch, Glenn A.; Appelbaum, Peter C.

doi:10.1016/j.cll.2004.03.008

Cited by 83 publications

(118 citation statements)

References 52 publications

Supporting

Mentioning

110

Contrasting

Unclassified

Order By: Relevance

“…71,72 Furthermore, multidrug-resistant S pneumoniae and β-lactamase-positive H influenzae and M catarrhalis are more commonly isolated after previous antibiotic exposure. [73][74][75][76][77][78] Unfortunately, there are no studies in children that have investigated the microbiology of treatment failure in acute bacterial sinusitis or cure rates using second-line antimicrobial agents. As a result, the likelihood of adequate antibiotic coverage for resistant organisms must be…”

Section: Key Action Statement 5bmentioning

confidence: 99%

Clinical Practice Guideline for the Diagnosis and Management of Acute Bacterial Sinusitis in Children Aged 1 to 18 Years

Wald,

Applegate,

Bordley

et al. 2013

Pediatrics

446

368

View full text Add to dashboard Cite

OBJECTIVE: To update the American Academy of Pediatrics clinical practice guideline regarding the diagnosis and management of acute bacterial sinusitis in children and adolescents. METHODS: Analysis of the medical literature published since the last version of the guideline (2001). RESULTS: The diagnosis of acute bacterial sinusitis is made when a child with an acute upper respiratory tract infection (URI) presents with (1) persistent illness (nasal discharge [of any quality] or daytime cough or both lasting more than 10 days without improvement), (2) a worsening course (worsening or new onset of nasal discharge, daytime cough, or fever after initial improvement), or (3) severe onset (concurrent fever [temperature ≥39°C/102.2°F] and purulent nasal discharge for at least 3 consecutive days). Clinicians should not obtain imaging studies of any kind to distinguish acute bacterial sinusitis from viral URI, because they do not contribute to the diagnosis; however, a contrast-enhanced computed tomography scan of the paranasal sinuses should be obtained whenever a child is suspected of having orbital or central nervous system complications. The clinician should prescribe antibiotic therapy for acute bacterial sinusitis in children with severe onset or worsening course. The clinician should either prescribe antibiotic therapy or offer additional observation for 3 days to children with persistent illness. Amoxicillin with or without clavulanate is the first-line treatment of acute bacterial sinusitis. Clinicians should reassess initial management if there is either a caregiver report of worsening (progression of initial signs/symptoms or appearance of new signs/symptoms) or failure to improve within 72 hours of initial management. If the diagnosis of acute bacterial sinusitis is confirmed in a child with worsening symptoms or failure to improve, then clinicians may change the antibiotic therapy for the child initially managed with antibiotic or initiate antibiotic treatment of the child initially managed with observation. CONCLUSIONS: Changes in this revision include the addition of a clinical presentation designated as “worsening course,” an option to treat immediately or observe children with persistent symptoms for 3 days before treating, and a review of evidence indicating that imaging is not necessary in children with uncomplicated acute bacterial sinusitis.

show abstract

Section: Key Action Statement 5bmentioning

confidence: 99%

Clinical Practice Guideline for the Diagnosis and Management of Acute Bacterial Sinusitis in Children Aged 1 to 18 Years

Wald,

Applegate,

Bordley

et al. 2013

Pediatrics

446

368

View full text Add to dashboard Cite

show abstract

“…A resistência a múltiplas drogas foi significativamente mais freqüente entre cepas resistentes do que entre cepas suscetíveis à penicilina 63 . Entre as cepas de H. influenzae, 28,6% eram produtoras de beta-lactamase, 70,2% foram suscetíveis a amoxicilina, 99,8% à combinação amoxicilina-ácido clavulânico, 82,8% a cefuroxime-axetil, 78,1% a sulfametoxazol-trimetoprim, 23,2% a cefprozil e 5% a cefaclor, azitromicina e claritromicina 63 .…”

Section: Resistência Antimicrobiana Dos Patógenos Respiratóriosunclassified

“…Entre as cepas de H. influenzae, 28,6% eram produtoras de beta-lactamase, 70,2% foram suscetíveis a amoxicilina, 99,8% à combinação amoxicilina-ácido clavulânico, 82,8% a cefuroxime-axetil, 78,1% a sulfametoxazol-trimetoprim, 23,2% a cefprozil e 5% a cefaclor, azitromicina e claritromicina 63 . A quase totalidade das cepas de M. catarrhalis foi resistente a amoxicilina, cefaclor, cefprozil e sulfametoxazol-trimetoprim, tendo sido a produção de beta-lactamase o mecanismo de resistência 63 .…”

Section: Resistência Antimicrobiana Dos Patógenos Respiratóriosunclassified

Outpatient antibiotic therapy as a predisposing factor for bacterial resistance: a rational approach to airway infections

Nascimento‐Carvalho¹

2006

J Pediatr (Rio J)

View full text Add to dashboard Cite

Objectives: To present evidence-based recommendations for the use of antibiotics for the treatment of the most common acute respiratory infections (ARI) and the available information on the importance of this type of management.Sources: MEDLINE and LILACS databases, technical publications by international organizations, national and international directives. The search terms acute respiratory infection, otitis, sinusitis, tonsillitis, pneumonia, antibiotic, guidelines and bacterial resistance were used. Articles cited by the articles selected were analyzed for information of interest.Summary of the findings: Bacterial resistance has grown, to the extent that today it is recognized as a global public health problem. ARI are the most common cause of antibiotic usage within the community; yet a large proportion of these cases, compromising the upper (otitis, sinusitis, tonsillitis) or the lower airways (pneumonia), are the result of viral infections. Recommendations to rationalize the use of antibiotics in patients with ARI have the common objective of minimizing unnecessary antibiotic use, since antibiotic pressure is one of the factors triggering bacterial resistance.Conclusions: It is of great importance to differentiate among ARI patients those who will benefit from the use of antibiotics. The establishment of recommendations for the prescription of antibiotics is one strategy for minimizing the frequency of bacterial resistance.J Pediatr (Rio J). 2006;82(5 Suppl):S146-52: Antibiotics, bacterial resistance, otitis, sinusitis, tonsillitis, pneumonia. ResumoObjetivos: Apresentar as recomendações baseadas em evidência para uso de antibióticos no tratamento das infecções respiratórias agudas (IRA) mais freqüentes e as informações disponíveis sobre a importância desse tipo de conduta.Fontes dos dados: Bases de dados MEDLINE, LILACS, publicações técnicas de organizações internacionais, diretrizes nacionais e internacionais. Foram utilizados os unitermos acute respiratory infection, otitis, sinusitis, tonsillitis, pneumonia, antibiotic, guidelines, bacterial resistance. Artigos citados pelos artigos incluídos foram analisados quanto à apresentação de informação de interesse. Síntese dos dados:A resistência bacteriana tem crescido, sendo atualmente reconhecida como problema mundial de saúde pública. As IRA são a causa mais freqüente para uso de antibiótico na comunidade; grande parte desses casos, tanto nas vias aéreas superiores (otite, sinusite, faringoamidalite) como nas inferiores (pneumonia), são decorrente de infecção viral. As recomendações para racionalizar o uso de antibióticos nos pacientes com IRA têm como objetivo comum minimizar o uso desnecessário de antibióticos, visto que a pressão antibióti-ca é um dos fatores desencadeantes da resistência bacteriana.Conclusões: É de grande importância a distinção, entre os pacientes com IRA, daqueles que podem se beneficiar do uso de antibióticos. O uso das recomendações para a prescrição de antibióticos é uma estratégia para minimizar a freqüência de resistên...

show abstract

“…[1][2][3][4][5][6] There is a great need for new antibiotics that address the problem of antibiotic resistance. Under these circumstances, a substantial amount study has been carried out on novel macrolides.…”

Section: Introductionmentioning

confidence: 99%

Synthesis and antibacterial activity of novel 4″-carbamates of 6,11-di-O-methylerythromycin A

Lü

Luo

et al. 2010

J Antibiot

View full text Add to dashboard Cite

A novel series of 4 00 -carbamates of 6,11-di-O-methylerythromycin A were synthesized and evaluated. These compounds have significant antibacterial activity against Gram-positive pathogens, including erythromycin-resistant but methicillin-susceptible Staphylococcus aureus, erythromycin-resistant and methicillin-resistant Staphylococcus aureus, erythromycin-resistant Streptococcus pneumoniae and Gram-negative pathogens, such as Haemophilus influenzae To our surprise, most of the derivatives tested had potent activity against most resistant bacteria. Among these, compounds 10u, 10v, 10w and 10y were found to have potent activity against most susceptible and resistant bacteria. In particular, compound 10y exhibited excellent antibacterial activity in comparison to others.

show abstract

Susceptibility of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 17 oral antimicrobial agents based on pharmacodynamic parameters: 1998–2001 U.S. Surveillance Study

Cited by 83 publications

References 52 publications

Clinical Practice Guideline for the Diagnosis and Management of Acute Bacterial Sinusitis in Children Aged 1 to 18 Years

Clinical Practice Guideline for the Diagnosis and Management of Acute Bacterial Sinusitis in Children Aged 1 to 18 Years

Outpatient antibiotic therapy as a predisposing factor for bacterial resistance: a rational approach to airway infections

Synthesis and antibacterial activity of novel 4″-carbamates of 6,11-di-O-methylerythromycin A

Contact Info

Product

Resources

About